stockrow
Saturday 7 November 2026
Export JBIO’s income statement to Excel — free account
Jade Biosciences, Inc.
JBIO Healthcare Biotechnology
- EPS
- +11.6%
- Free cash flow
- −115.1%
Quarter to June 2026, against a year earlier
15.03
0.93
+6.60%
Follow JBIO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (3) | (10) | (23) | (51) | (75) | (47) | (127) | (153) | +83.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (3) | (10) | (23) | (52) | (76) | (47) | (127) | (153) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (484.82) | (1,393.50) | (65.61) | (73.68) | (100.70) | (14.89) | (3.19) | (2.30) | (56.7%) | ||||||
| Cash flow | — | — | — | (403.04) | (1,138.99) | (78.19) | (56.09) | (75.65) | (7.17) | (3.02) | (2.02) | (55.8%) | ||||||
| Capex | — | — | — | 0.00 | 0.00 | (0.52) | (0.28) | (0.19) | 0.00 | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (403.04) | (1,138.99) | (78.71) | (56.37) | (75.84) | (7.17) | (3.03) | (2.02) | (55.8%) | ||||||
| Book value | — | — | — | (527.97) | (1,933.91) | 492.06 | 181.71 | 145.84 | (14.83) | 10.60 | 7.21 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 0 | 1 | 1 | 3 | 31 | 47 | +307.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (8) | (27) | (39) | (57) | (23) | (95) | (124) | +80.0% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | — | 0 | 0 | +2.0% | ||||||
| Free cash flow | — | — | — | (3) | (8) | (28) | (39) | (57) | (23) | (95) | (124) | +80.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 3 | 3 | 172 | 124 | 107 | 58 | 332 | 440 | +120.9% | |||||
| Net debt | — | — | — | (1) | (5) | (167) | (129) | (122) | 38 | (336) | (461) | +163.1% | ||||||
| Shareholders’ equity | — | — | — | (4) | (13) | 172 | 127 | 109 | (47) | 333 | 440 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (189.53) | (233.59) | (25.50) | (33.16) | (57.49) | (46.93) | (47.39) | (42.54) | +142.1 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (265.23) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 39.21 | 113.16 | (28.87) | (34.44) | (63.95) | (149.96) | (70.09) | (46.16) | (109.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 8 | 16 | 43 | 51 | 4 | 55 | — | +47.0% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Jade Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMTX Immatics N.V. | $924.8M | — (loss-making) | — (loss-making) | +97.71% (above 0%: growing) | n/m | −44.41% (below 0%: shrinking) | 100.00% | (734.95%) | Compare |
| MLTX MoonLake Immunotherapeutics | $919.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ODTX Odyssey Therapeutics, Inc. | $907.3M | — (loss-making) | — | — | n/m | — | 100.00% | 0.00% | Compare |
| SVRA Savara Inc. | $899.9M | — (loss-making) | — (loss-making) | — | n/m | −14.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| JBIO Jade Biosciences, Inc. | $896.7M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | |
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $874.5M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $870.6M | 34.2× | — (loss-making) | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| Median of peers | $891.4M | — | — | +97.71% | — | −8.74% | 86.90% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
23.06%
Entities affiliated with Fairmount Funds Management LLC
19.99%
Tomas Kiselak
19.99%
FMR LLC
13.98%
Entities affiliated with Venrock Healthcare Capital Partners
9.99%
Entities affiliated with Bellevue Group AG
6.77%
RA Capital Healthcare Fund, L.P.
6.52%
Biotech Growth N.V.
6.52%
Entities Affiliated with Janus Henderson Investors US LLC
6.21%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement